Advertisement

Harrow, Inc. HROW

Set alert

Price alert · HROW

All alert types
28.24 USD -1.75 -5.84%

At close · Oct 30

28.24 0.00 0.00%

After hours · Oct 30, 4:00 PM ET

Bid
28.21 × 2
Ask
28.24 × 2
28.08 Day range 30.05
27.24 52-week range 54.80
YTD
-42.37%
1 year
-24.81%
Open
29.69
Prev close
29.99
Mkt cap
1.06B
Vol
335.28K
Avg vol
571.02K
EPS
-0.99
P/E
0.00
Div yield
0.00%
More statistics
Low
28.08
High
30.05
Forward P/E
10.19
Beta
0.18
Short ratio
11.49
Inst. own
58.62%
Dividend
0.00
Ex-div date
Earnings
Nov 9, 2026
50-d avg
33.14
200-d avg
38.45
1y target
63.00

2Y chart

Chart tools
Interval

Events in this range
  • Aug 11, 2025Earnings: 0.14; estimate 0.00755; surprise 1754.3%
  • Nov 10, 2025Earnings: 0.03; estimate 0.22; surprise -86.36%
  • Mar 2, 2026Earnings: 0.18; estimate 0.4; surprise -55%
  • May 11, 2026Earnings: -0.74; estimate -0.43; surprise -72.09%
  • May 12, 2026Rating: BTIG · Buy → Buy
  • May 13, 2026Rating: Cantor Fitzgerald · Overweight → Overweight
  • Jul 21, 2026Rating: BTIG · Buy → Buy
  • Aug 10, 2026Earnings: -0.46; estimate -0.17875; surprise -157.34%
  • Aug 11, 2026Rating: BTIG · Buy → Buy
  • Sep 9, 2026Rating: Leerink Partners · — → Outperform
  • Oct 7, 2026Rating: BTIG · Buy → Buy
Signals (100)
NameDateAgo
MACD: Buy SignalOct 20, 20261 week ago
RSI: OversoldOct 16, 20262 weeks ago
RSI: OversoldSep 28, 20261 month ago
MACD: Sell SignalAug 27, 20262 months ago
SMA: BearishAug 26, 20262 months ago
SMA: BullishAug 25, 20262 months ago
SMA: BearishAug 21, 20262 months ago
SMA: BearishAug 21, 20262 months ago
SMA: BullishAug 19, 20262 months ago
SMA: BullishAug 19, 20262 months ago
MACD: Buy SignalAug 19, 20262 months ago
SMA: BearishAug 11, 20262 months ago
SMA: BearishAug 5, 20262 months ago
SMA: BullishAug 4, 20262 months ago
SMA: BearishJul 29, 20263 months ago
SMA: BullishJul 28, 20263 months ago
SMA: BearishJul 24, 20263 months ago
SMA: BearishJul 24, 20263 months ago
MACD: Sell SignalJul 10, 20263 months ago
RSI: OverboughtJul 6, 20263 months ago
SMA: BullishJun 30, 20264 months ago
SMA: BearishJun 29, 20264 months ago
RSI: OverboughtJun 23, 20264 months ago
RSI: OverboughtJun 18, 20264 months ago
SMA: BullishJun 17, 20264 months ago
SMA: BullishJun 11, 20264 months ago
MACD: Buy SignalMay 27, 20265 months ago
SMA: BearishMay 12, 20265 months ago
RSI: OversoldMay 12, 20265 months ago
MACD: Sell SignalMay 7, 20265 months ago
SMA: BearishApr 28, 20266 months ago
SMA: BullishApr 27, 20266 months ago
SMA: BullishApr 27, 20266 months ago
SMA: BearishApr 20, 20266 months ago
SMA: BearishApr 20, 20266 months ago
SMA: BullishApr 17, 20266 months ago
SMA: BullishApr 17, 20266 months ago
MACD: Buy SignalMar 25, 20267 months ago
RSI: OversoldMar 20, 20267 months ago
RSI: OversoldMar 13, 20267 months ago
RSI: OversoldMar 5, 20268 months ago
SMA: BearishMar 3, 20268 months ago
SMA: BearishMar 3, 20268 months ago
MACD: Sell SignalMar 3, 20268 months ago
RSI: OversoldMar 3, 20268 months ago
SMA: BullishFeb 13, 20268 months ago
SMA: BearishFeb 12, 20268 months ago
SMA: BullishFeb 6, 20268 months ago
SMA: BearishFeb 5, 20268 months ago
MACD: Buy SignalFeb 5, 20268 months ago
SMA: BullishFeb 3, 20269 months ago
SMA: BearishJan 22, 20269 months ago
MACD: Sell SignalJan 9, 20269 months ago
MACD: Buy SignalJan 5, 20269 months ago
RSI: OverboughtJan 5, 20269 months ago
MACD: Sell SignalJan 2, 202610 months ago
MACD: Buy SignalDec 23, 202510 months ago
MACD: Sell SignalDec 17, 202510 months ago
RSI: OverboughtDec 10, 202510 months ago
SMA: BullishDec 3, 202511 months ago
SMA: BearishDec 1, 202511 months ago
SMA: BullishNov 25, 202511 months ago
MACD: Buy SignalNov 12, 202511 months ago
SMA: BearishOct 21, 20251 year ago
SMA: BullishOct 20, 20251 year ago
SMA: BearishOct 10, 20251 year ago
SMA: BullishOct 9, 20251 year ago
SMA: BearishOct 8, 20251 year ago
MACD: Sell SignalOct 3, 20251 year ago
RSI: OverboughtSep 22, 20251 year ago
RSI: OverboughtSep 18, 20251 year ago
MACD: Buy SignalSep 15, 20251 year ago
MACD: Sell SignalSep 2, 20251 year ago
RSI: OverboughtAug 14, 20251 year ago
MACD: Buy SignalAug 13, 20251 year ago
SMA: BullishAug 4, 20251 year ago
SMA: BearishAug 1, 20251 year ago
MACD: Sell SignalJul 28, 20251 year ago
RSI: OverboughtJul 21, 20251 year ago
MACD: Buy SignalJul 11, 20251 year ago
RSI: OverboughtJul 11, 20251 year ago
MACD: Sell SignalJun 23, 20251 year ago
MACD: Buy SignalMay 29, 20251 year ago
MACD: Sell SignalMay 28, 20251 year ago
SMA: BullishMay 12, 20251 year ago
SMA: BearishMay 5, 20251 year ago
SMA: BullishMay 2, 20251 year ago
MACD: Buy SignalApr 23, 20251 year ago
MACD: Sell SignalApr 21, 20251 year ago
MACD: Buy SignalApr 17, 20251 year ago
MACD: Sell SignalApr 3, 20251 year ago
SMA: BearishMar 25, 20251 year ago
SMA: BullishMar 24, 20251 year ago
MACD: Buy SignalMar 18, 20251 year ago
RSI: OversoldMar 6, 20251 year ago
RSI: OversoldMar 3, 20251 year ago
MACD: Sell SignalFeb 24, 20251 year ago
MACD: Buy SignalFeb 10, 20251 year ago
MACD: Sell SignalJan 29, 20251 year ago
MACD: Buy SignalDec 26, 20241 year ago

Key statistics

Market cap
1.06B
Enterprise value
1.34B
Trailing P/E
0.00
Forward P/E
10.19
PEG ratio
0.00
Price / sales
3.84
Price / book
69.56
EPS (TTM)
-0.99
Beta
0.18
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-13.51%
Revenue (TTM)
275.59M
Revenue growth
10.90%
Free cash flow
-5.49M
Total cash
85.32M
Total debt
300.74M
Return on equity
-116.07%
Shares outstanding
37.49M
Short % of float
22.19%
50-day average
33.14
200-day average
38.45

Analyst view

Consensus: none

Price target (mean) 63.00 +123.1% upside
Target (low)
45.00
Target (mean)
63.00
Target (high)
88.00
Ratings (0m) 9 9 buy · 0 hold · 0 sell
  • Strong buy0
  • Buy9
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

Nov 9, 2026

Expected Nov 9, 2026. Consensus EPS estimate 0.32.

Earnings history

Financials — quick view

All financials
HROW Revenue — quarterly 70.66M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
HROW Net income — quarterly -17.27M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
HROW EPS — quarterly -0.46
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

HROW recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 9, 2026Sep 30, 20260.17———
Aug 10, 2026Jun 30, 2026-0.17875-0.46-0.28-157.34%
May 11, 2026Mar 31, 2026-0.43-0.74-0.31-72.09%
Mar 2, 2026Dec 31, 20250.400.18-0.22-55.00%
Nov 10, 2025Sep 30, 20250.220.03-0.19-86.36%
Aug 11, 2025Jun 30, 20250.007550.14+0.13+1,754.30%

Upgrades / downgrades

HROW analyst upgrades and downgrades
DateFirmActionFromTo
Oct 7, 2026BTIGreitBuyBuy
Sep 9, 2026Leerink Partnersinit—Outperform
Aug 11, 2026BTIGreitBuyBuy
Jul 21, 2026BTIGreitBuyBuy
May 13, 2026Cantor FitzgeraldmainOverweightOverweight
May 12, 2026BTIGreitBuyBuy

About Harrow, Inc.

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
United States
Website
harrow.com

News

Your note

Sign in to keep a note on HROW — it syncs with the Stock Master app.

Insider holders

HROW insider holders
InsiderRelationLatest transactionDateShares held
BAUM MARK LChief Executive OfficerPurchaseMay 13, 20262,996,130
BOLL ANDREW RPresidentPurchaseMay 13, 2026814,679
GRAVES ADRIENNE LDirectorPurchaseMay 17, 20261,000
OPALEYE MANAGEMENT, INC.Beneficial Owner of more than 10% of a Class of SecuritySaleMar 3, 20260
SAHAREK JOHN PChief Executive OfficerConversion of Exercise of derivative securityApr 2, 2025467,388
SHOJAEI AMIROfficerConversion of Exercise of derivative securityAug 13, 20260

Institution ownership

HROW institution ownership
Holder% heldSharesValueReported
Blackrock Inc.7.31%2,740,11777.38MJun 29, 2026
Opaleye Management Inc.6.40%2,400,00067.78MJun 29, 2026
Private Capital Management, LLC4.26%1,598,77045.15MJun 29, 2026
Vanguard Capital Management LLC3.78%1,417,21240.02MJun 29, 2026
Deep Track Capital, Lp2.58%969,00027.36MJun 29, 2026
State Street Corporation2.51%939,88826.54MJun 29, 2026

Fund ownership

HROW fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.67%1,001,44528.28MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.23%836,79323.63MSep 29, 2026
BARON INVESTMENT Fd.S TRT -BARON DISCOVERY Fd.1.54%576,06916.27MJun 29, 2026
JANUS INVESTMENT FUND-Janus Henderson Venture Fund1.25%468,45113.23MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund1.02%383,78110.84MJun 29, 2026
Fidelity Salem Street Trust-Fidelity Small Cap Index Fund0.94%353,7409.99MJul 30, 2026
Advertisement